Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
NCT05010005Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2021
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib and duvelisib in T-cell lymphoma, natural killer cell lymphoma (NKCL), T-cell prolymphocytic leukemia (T-PLL) and 1 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose / Optimal Dose at 1 year. Started Aug 2021; status: active, not recruiting.
02
Drugs
ruxolitinibduvelisib
03
Conditions
T-cell lymphomanatural killer cell lymphoma (NKCL)T-cell prolymphocytic leukemia (T-PLL)T-cell large granular lymphocytic leukemia (T-LGLL)
Beyond the preview
Go deeper on NCT05010005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05010005.